Candriam S.C.A. Has $62.96 Million Stake in Agilent Technologies, Inc. $A

Candriam S.C.A. grew its position in Agilent Technologies, Inc. (NYSE:A) by 2.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 533,466 shares of the medical research company’s stock after purchasing an additional 12,510 shares during the quarter. Candriam S.C.A. owned approximately 0.19% of Agilent Technologies worth $62,957,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Impax Asset Management Group plc boosted its position in Agilent Technologies by 3.1% during the second quarter. Impax Asset Management Group plc now owns 3,022,842 shares of the medical research company’s stock valued at $356,726,000 after acquiring an additional 91,048 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Agilent Technologies by 3.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 43,058 shares of the medical research company’s stock valued at $5,081,000 after purchasing an additional 1,268 shares during the period. Bailard Inc. boosted its position in shares of Agilent Technologies by 14.3% during the 2nd quarter. Bailard Inc. now owns 3,007 shares of the medical research company’s stock valued at $355,000 after purchasing an additional 376 shares in the last quarter. Geode Capital Management LLC grew its stake in Agilent Technologies by 1.6% during the second quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company’s stock worth $860,137,000 after purchasing an additional 115,183 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in Agilent Technologies by 1.4% in the second quarter. PNC Financial Services Group Inc. now owns 177,876 shares of the medical research company’s stock worth $20,991,000 after purchasing an additional 2,402 shares in the last quarter. Institutional investors own 87.41% of the company’s stock.

Agilent Technologies Stock Up 1.4%

Shares of NYSE:A opened at $151.53 on Thursday. The business’s 50 day moving average is $136.91 and its 200 day moving average is $123.33. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The stock has a market cap of $42.96 billion, a price-to-earnings ratio of 35.57, a PEG ratio of 4.67 and a beta of 1.29. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business’s revenue was up 10.1% on a year-over-year basis. During the same period last year, the business earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th were issued a dividend of $0.248 per share. The ex-dividend date was Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.7%. Agilent Technologies’s payout ratio is 23.24%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on A. Rothschild Redb upgraded Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. Evercore ISI boosted their target price on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research report on Tuesday, October 7th. Wells Fargo & Company raised their price objective on Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, September 15th. UBS Group upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $130.00 to $170.00 in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their target price on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $149.62.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.